Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

New research shows diabetes drugs may significantly reduce the risk of dementia, Alzheimer's, and Parkinson’s disease.

Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By ...

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study ...

The cause of Parkinson's Disease remains largely unknown, but a new drug could be extremely beneficial to treat symptoms.

A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.

Health service announces three-year safety improvement programme to ensure patients receive critical medicine on time ...

Increased exposure to air pollution in the form of particulate matter with a diameter of 2.5 µm or less (PM2.5) and nitrogen ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk ...